Product information and disease descriptionProduct descriptionProduct information
Special populations
9 evidence topics · 2 sources
Crizotinib label: pregnancy
Crizotinib label: lactation
Crizotinib label: pregnancy testing, contraception, and infertility
Crizotinib label: geriatric use
Crizotinib label: hepatic impairment, with dose reduction for moderate or severe impairment
Crizotinib label: renal impairment, with dose reduction for severe impairment not requiring dialysis
OptimUM-02 EU trial record: renal and hepatic function thresholds
OptimUM-02 EU trial record: cardiac exclusions and heart rate threshold
OptimUM-02 EU trial record: contraception for 6 months in women and 3 months in men after the last dose
Darovasertib pharmacokinetics in hepatic or renal impairment
No evidence found.